Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / ALRN - Aileron to announce PoC data from early-stage study with chemoprotection agent

ALRN - Aileron to announce PoC data from early-stage study with chemoprotection agent

Aileron Therapeutics Inc.
Aileron Therapeutics ([[ALRN]] +11.6%) has announced that proof-of-concept (PoC) data from Phase 1b study of ALRN-6924 will be featured during EORTC-NCI-AACR Annual Symposium on Molecular Targets and Cancer Therapeutics, being held virtually October 24 – 25.The Phase 1b study is evaluating ALRN-6924, a chemo-protection agent administered ahead of chemotherapy to prevent chemotherapy-induced toxicities, in patients with p53-mutated small cell lung cancer ((SCLC)) who are being treated with the chemotherapy topotecan. In June, Aileron announced positive interim data from this study.

For further details see:

Aileron to announce PoC data from early-stage study with chemoprotection agent
Stock Information
Company Name: Aileron Therapeutics Inc.
Stock Symbol: ALRN
Market: NASDAQ
Website: aileronrx.com
Menu
ALRN ALRN Quote ALRN Short ALRN News ALRN Articles ALRN Message Board
Get ALRN Alerts

News, Short Squeeze, Breakout and More Instantly...